Clinical Trials Logo

Malabsorption Syndromes clinical trials

View clinical trials related to Malabsorption Syndromes.

Filter by:

NCT ID: NCT00816842 Completed - Clinical trials for Malabsorption Syndromes

Plasma Citrulline Concentration in Tropical Enteropathy

Start date: October 1998
Phase: N/A
Study type: Observational

Citrulline is an amino acid produced in the intestine and in the liver, but the liver does not contribute significantly to circulating citrulline concentrations. The intestine is thus the only organ that normally releases significant amounts of citrulline into the blood stream. The investigators have designed a study looking at the value of measuring plasma citrulline concentration in patients with tropical enteropathy of mixed HIV status. The focus will be on the ability of the intestine to sustain the individual concerned from a nutritional standpoint. The investigators hypothesise that plasma citrulline concentration is a marker of small bowel absorptive integrity and an appropriate surrogate for HIV related enteropathy.

NCT ID: NCT00662675 Completed - Cystic Fibrosis Clinical Trials

A Study of the Efficacy and Tolerability of Pancrelipase Microtablet (MT) Capsules for the Treatment of Cystic Fibrosis-dependent Exocrine Pancreatic Insufficiency

Start date: August 2008
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the effectiveness and safety of oral pancrelipase MT in the treatment of adult and pediatric/adolescent cystic fibrosis (CF) patients with clinical symptoms of exocrine pancreatic insufficiency (EPI).

NCT ID: NCT00572975 Completed - Cystic Fibrosis Clinical Trials

Malabsorption Blood Test:Toward a Novel Approach to Quantify Steatorrhea

MBT
Start date: August 2006
Phase: Phase 4
Study type: Interventional

*The purpose of this study is to develop a more accurate, reliable, specific and more acceptable alternative clinical test to the 72-hour stool and diet collection for quantifying fat malabsorption in people with CF and pancreatic insufficiency.

NCT ID: NCT00555191 Completed - Clinical trials for Irritable Bowel Syndrome

Fructose Malabsorption in Northern Norway

FINN
Start date: September 2007
Phase: Phase 2/Phase 3
Study type: Interventional

Different published studies has shown a possible co-variation between leakage of fructose to the great bowel and exacerbation of irritable bowel syndrome (IBS) symptoms. The aim of the FINN trial is to study the role of fructose malabsorption in patients with IBS in order to evaluate different diagnostic criteria for fructose malabsorption and at the same time study the effect of diet treatment in this cohort of patients and estimate the prevalence of fructose malabsorption.

NCT ID: NCT00521703 Completed - Clinical trials for Gastroesophageal Reflux Disease

Evaluation of Topical Lidocaine Spray as Adjuvant to Upper Gastrointestinal Endoscopy in Children

Start date: August 2007
Phase: Phase 3
Study type: Interventional

There is some controversy in the medical literature regarding the effectiveness of topical lidocaine in children as an adjuvant drug to upper gastrointestinal endoscopy. In children, deep sedation and general anesthesia are often used to sedate children submitting to this procedure. Propofol is an anesthetic drug increasingly popular in this situation, but this drug can only be used with an anesthesiologist in Brazil. Its main side effects include hypotension, respiratory depression and local pain. Lidocaine is frequently used as premedication, and the rationale is that lowering patient discomfort could lower the required dose to achieve the endoscopy and reduce potential side effects. Nevertheless, some patients perceive this medication as uncomfortable. This study aims to compare sedative drug doses between patients who were given either placebo or topical lidocaine.

NCT ID: NCT00456729 Completed - Iron Deficiency Clinical Trials

Malabsorption as a Cause of Iron Treatment Failure in Infants

Start date: May 2006
Phase: N/A
Study type: Interventional

Infants should receive prophylacatic iron supplementation since age 4 months till one year. Patients suffering from malabsorption, mainly Giardia infestation may develop iron deficiency resistent to further iron treatment. The purpose of this study is to assess the incidence of malabsorption in those infants and to examine the results of empiric treatment with metronidazole.

NCT ID: NCT00217204 Completed - Cystic Fibrosis Clinical Trials

An Effectiveness, Safety, and Palatability Study of Pancrelipase Microtablets in Infants and Toddlers With Cystic Fibrosis and Fat Malabsorption

Start date: July 2005
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the effectiveness and safety of PANCREASE MT (pancrelipase microtablets) to improve steatorrhea (excessive excretion of fat in feces) in infants and toddlers with cystic fibrosis who have pancreatic insufficiency, and to assess whether the consistency of the microtablets is acceptable for swallowing in infants and toddlers

NCT ID: NCT00163813 Not yet recruiting - Critical Illness Clinical Trials

The Early Nasojejunal Tube to Meet Energy Requirements in Intensive Care (ENTERIC) Study

ENTERIC
Start date: n/a
Phase: N/A
Study type: Interventional

This is a multi-centre randomised controlled trial comparing early jejunal feeding (using a frictional nasojejunal [NJ] tube) and standard feeding in critical illness.

NCT ID: NCT00138879 Completed - Crohn's Disease Clinical Trials

Citrulline: A Plasmatic Marker to Assess and Monitor Small Bowel Crohn's Disease Patients

Start date: May 2003
Phase: N/A
Study type: Observational

Citrulline is an amino acid produced in the intestine and in the liver, but the liver does not contribute significantly to circulating citrulline concentrations. The intestine is thus the only organ that normally releases significant amounts of citrulline into the blood. The investigators have designed a study looking at the value of measuring plasma citrulline concentration in patients with Crohn’s disease and short bowel or normal intestinal length. Measuring the plasma citrulline concentration in short bowel patients may help to distinguish between patients who need permanent parenteral feeding from patients with just transient intestinal dysfunction. It may also help the investigators in understanding the small bowel intestinal length remaining and the absorptive integrity. In patients with normal intestinal length and Crohn’s disease, it may be a reliable marker of small bowel damage and could be applied to establish therapeutic improvements. It has been demonstrated to strongly correlate (inversely) with severity on intestinal biopsies. The investigators hypothesise that the plasma citrulline concentration is a marker for small bowel absorptive integrity and an appropriate surrogate for functional length of the small intestine. Controlled data do not yet exist to establish the place of plasma citrulline in the assessment of small bowel function in man.